Lakefront Biotherapeutics NV current report, Q4 FY2023

SEC Filing Summary: Form 6-K

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of December 2023. The filing, dated December 12, 2023, incorporates by reference a press release issued on December 7, 2023 (Exhibit 99.1). The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Form 20-F.

Financial Metrics

The provided filing text serves as a cover sheet and does not contain specific financial data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.

Material Changes

No material financial changes or comparative period data are disclosed in the text of this Form 6-K. The filing solely references the issuance of a press release.

Guidance, Outlook, and Risks

The text does not include management commentary, guidance, outlook, or specific risk factors. It states that the information in the attached press release (Exhibit 99.1) is incorporated by reference into various Registration Statements on Form S-8.

Key Facts for Investor Verification

  • Entity Discrepancy: The metadata lists "Lakefront Biotherapeutics NV," but the filing is explicitly for "Galapagos NV." Investors must verify the correct entity.
  • Missing Content: The actual content of the December 7, 2023, press release (Exhibit 99.1) is not included in the provided text; investors must locate the exhibit to understand the material event.
  • No Financials: This specific document contains no financial statements or metrics.
  • Form S-8 Reference: The press release information is incorporated into multiple Form S-8 registration statements, which may be relevant for employee stock plans.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.